Conformis

Conformis FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Conformis (CFMS) as of Oct 23, 2026 is 103.17 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 443.39 % — a change of -76.73% (lower).

FCF Conversion

103.17 %

YoY

-76.73%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Conformis is 2022 103.17 % . FCF Conversion Rate (FCF/EBITDA) of Conformis was 2021 443.39 % . It decreases by -76.73% lower compared to the previous year.

The Conformis FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
103.23 USD
Jan 1, 2016
97.75 USD
Jan 1, 2017
80.42 USD
Jan 1, 2018
71.58 USD
Jan 1, 2019
20.24 USD
Jan 1, 2020
88.75 USD
Jan 1, 2021
443.39 USD
Jan 1, 2022
103.17 USD
The Conformis FCF Conversion history
YEARFCF ConversionYoY
103.17 %-76.73%
443.39 %+399.62%
88.75 %+338.46%
20.24 %-71.72%
71.58 %-10.99%
80.42 %-17.73%
97.75 %-5.31%
103.23 %+2.26%
100.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Conformis Stock analysis

What does Conformis do? Conformis Inc is a medical technology company that specializes in the development, manufacturing, and marketing of customized implantable joint prostheses. The company is based in the United States and has its headquarters in Billerica, Massachusetts. History: Conformis Inc was founded in 2004 by Dr. Philipp Lang, an orthopedic surgeon and pioneer in the development of customized implants. The company's goal was to develop an innovative technology that could be used to manufacture individual prostheses for patients. Initially, Conformis focused on the development of custom prostheses for the knee joint. Over the years, the company has expanded its offerings to include other joints such as the hip. Business model: Conformis' business model is based on providing customized, implantable prostheses. Unlike traditional prostheses that are available in standard sizes, Conformis prostheses are individually manufactured for each patient. The company uses advanced 3D printing technology to produce a prosthesis that matches the specific anatomical features of the patient. Conformis prostheses offer numerous advantages over conventional prostheses. By customizing the prosthesis, a better fit and higher stability can be achieved. This can lead to better function and increased lifespan of the prosthesis. Additionally, Conformis prostheses can be implanted faster and more easily than traditional prostheses. Divisions: Conformis offers a variety of products for different joints. Knee prostheses: Conformis offers a wide range of custom knee prostheses. The offerings include partial replacement prostheses that only replace a part of the knee, as well as complete knee prostheses. All prostheses are individually manufactured for each patient to ensure optimal fit and function. Hip prostheses: Conformis also offers custom prostheses for the hip. These prostheses are designed to provide high stability and better fit. The hip prostheses are also individually made for each patient. Shoulder prostheses: Conformis offers custom prostheses for the shoulder, which are also tailored to the patient's anatomy. These prostheses can be used for rotator cuff defects as well as other shoulder problems. Products: The core product of Conformis is custom joint prostheses. The company's prostheses are individually manufactured for each patient to ensure optimal fit and function. Advanced technologies such as 3D printing and digital imaging are used in the production process. Conformis also offers implants for specialized procedures such as medial knee replacement. In addition to the prostheses, Conformis also offers implants such as screws, pins, and plates that can be used to fix bones during surgery. Conclusion: Conformis is a leading company in the medical technology field and offers specialized products that cater to the needs of patients. The company specializes in customized implantable joint prostheses and offers a wide range of products that are tailored to the needs of patients. Conformis has earned an excellent reputation in the industry and continues to strive to develop innovative products that improve the lives of patients. Conformis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Conformis stock

FCF Conversion Rate (FCF/EBITDA) of Conformis is 103.17 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of Conformis changed from 443.39 % to 103.17 %, representing a -76.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Conformis since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Conformis with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Conformis

All Key Metrics — Conformis